Evidence map›Paper›PMID 33910530›Full record

ArticleBMC cancer2021

MACE-Seq-based coding RNA and TrueQuant-based small RNA profile in breast cancer: tumor-suppressive miRNA-1275 identified as a novel marker.

Sevan Omer Majed, Suhad Asad Mustafa

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Delineating highly transcribed noncoding elements landscape in breast cancer.Computational and structural biotechnology journal · 2023
    Article
  4. Article
  5. Role and Dysregulation of miRNA in Patients with Parkinson's Disease.International journal of molecular sciences · 2022
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Sevan Omer MajedBiology Department, College of Education, Salahaddin University-Erbil, Erbil, Iraq. sevan.majed@su.edu.krd.
Suhad Asad MustafaResearch Center, Molecular Genetics lab, Salahaddin University-Erbil, Erbil, Iraq.
Salahaddin University-Erbil · IQ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionDisruption of cellular processes in the breast by abnormally expressed miRNA is characterized to develop cancer. We aimed to identify the differential expression of small RNAs (sRNAs) and mRNAs in formalin-fixed paraffin-embedded (FFPE) tissue of the breast cancer (BC) and normal adjacent tissue (NAT). Another aim is to determine the differential expression of miR-1275 as a novel biomarker for BC and also identify its target genes.

methodsTrueQuant method for analysis of sRNA expression and MACE-sequencing method for analysis of gene expression were used analyzing. The RT-qPCR technique was used to confirm miR-1275 down expression. Target genes of miR-1275 were computationally identified using target prediction sites and also the expression level of them was experimentally determined among the expressed genes.

resultsTrueQuant findings showed that 1400 sRNAs were differentially expressed in the FFPE tissue of two Kurdish cases with BC, as compared to NAT. Among the sRNAs, 29 small RNAs were shown to be significantly downregulated in BC cells. The RT-qPCR results confirmed that miR-1275 was significantly down-expressed in 20 Kurdish cases with BC compared to NAT. However, Overall survival (OS) analysis revealed that the correlation between the expression level of miR-1275 and clinical significance was highly corrected in cases with BC (OS rate: P = 0.0401). The MACE-seq results revealed that 26,843 genes were differentially expressed in the BC tissue compared to NAT, but 7041 genes were displayed in a scatter plot. Furthermore, putative target genes (DVL3, PPP2R2D, THSD4, CREB1, SYT7, and PRKACA) were computationally identified as direct targets of miR-1275 in several target predicted sites. The MACE-seq results revealed that the expression level of these targets was increased in BC tissue compared to NAT. The level of these targets was negatively associated with miR-1275 expression. Finally, the role of down-regulated miR-1275 on its targets in biological mechanisms of BC cells was identified; including cell growth, proliferation, movement, invasion, metastasis, and apoptosis.

conclusionDown-expressed miR-1275, a tumor suppressor, is a novel biomarker for early detection of BC. DVL3, PPP2R2D, THSD4, CREB1, SYT7, and PRKACA are newly identified to be targeted by miR-1275.

Indexed as

ADAM ProteinsAdolescentAdultAgedBiomarkers, TumorBreastBreast NeoplasmsCyclic AMP-Dependent Protein Kinase Catalytic SubunitsCyclic AMP Response Element-Binding ProteinDishevelled ProteinsDown-RegulationFemaleGene ExpressionGene Expression ProfilingGene LibraryHumansADAM ProteinsBiomarkers, TumorCREB1 protein, humanCyclic AMP-Dependent Protein Kinase Catalytic SubunitsCyclic AMP Response Element-Binding ProteinDishevelled ProteinsDVL3 protein, humanMicroRNAsMIRN1275 microRNA, humanPPP2R2D protein, humanPRKACA protein, humanProtein Phosphatase 2RNA, NeoplasmSynaptotagminsSYT7 protein, humanTHSD4 protein, humanTumor Suppressor ProteinsAnd tumor suppressorBreast cancermiR-1275 and its target genesmiRNAPathogenesisSmall RNA and gene expression

Identifiers

PMID33910530
PMCPMC8082896
OpenAlexW3129523220

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.